Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Casper (CSPR) fluctuated 43.6% within 24 hours: Mainnet V2.2.0 upgrade triggers severe price volatility

Casper (CSPR) fluctuated 43.6% within 24 hours: Mainnet V2.2.0 upgrade triggers severe price volatility

Bitget PulseBitget Pulse2026/03/24 22:02
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, the price of CSPR touched a low of $0.003518 and a high of $0.005053, with the current quote at $0.003661, reflecting a fluctuation range of 43.6%. Trading volume surged significantly, with 24-hour turnover between approximately $17.8 million and $25.99 million, spiking by over 1400% compared to the previous day.

Analysis of Causes for Unusual Activity

- Casper Network’s mainnet underwent a protocol-level hard fork upgrade V2.2.0 on March 23, 2026, introducing a 100% transaction fee burning mechanism and reducing block time cap to 8 seconds. This event directly triggered intense price volatility, with 24-hour volatility reaching 50.7%.

- Multiple exchanges (such as Bybit, MEXC) suspended CSPR deposits and withdrawals on March 23 to support the upgrade, further amplifying market liquidity fluctuations.

Market Views and Outlook

Community sentiment is mainly neutral to optimistic. Discussions on X platform focus on upgrade benefits such as enterprise-level RWA settlement potential and technical buy signals (e.g., 4-hour RSI rebounding above 50), while some viewpoints warn about short-term minting supply concerns. Analysts suggest that prices may stabilize after the upgrade, but stress the need to monitor sell-off risks in a low-liquidity environment.

Note: This analysis is generated automatically by AI based on public data and on-chain monitoring and is for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23